JAMA Neurology

, volume 77 , issue 2 , pages 184

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna ¹

Peter Alping ^{1, 2}

Joachim Burman ³

Katharina Fink ²

A. Fogdell-Hahn ²

M. Gunnarsson ⁴

Jan Hillert ²

A. Langer-Gould ⁵

J. Lycke ⁶

Petra Nilsson ⁷

J. Salzer ⁸

Anders Svenningsson ⁹

Magnus Vrethem ¹⁰

T. Olsson ²

Fredrik Piehl ^{2, 11, 12}

Thomas Frisell ¹

Hide authors affiliations Show authors affiliations: 12 affiliations

Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden |

Department of clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden |

Department of neuroscience, Uppsala University, Uppsala, Sweden |

⁴

Center for Health and Medical Psychology, Örebro University, Örebro, Sweden |

⁵

Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente, Pasadena |

⁶

Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, Gothenburg, Sweden |

⁷

Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden |

⁸

Department of Pharmacology and Clinical Neuroscience, Umea University, Umea, Sweden |

⁹

Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden |

¹⁰

Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden |

¹¹

Department of Neurology, Karolinska University hospital, Stockholm, Sweden |

¹²

Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden |

Publication type: Journal Article

Publication date: 2020-02-01

American Medical Association (AMA)

JAMA Neurology

scimago Q1

wos Q1

SJR: 6.237

CiteScore: 31.0

Impact factor: 21.3

ISSN: 21686149, 21686157

DOI: 10.1001/jamaneurol.2019.3365

Copy DOI

PubMed ID: 31589278

Neurology (clinical)

Abstract

Importance: Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and g ...

Found

1 citation

Kupriyanov Semyon

🤝

PhD in Health sciences

8 publications, 4 citations

h-index: 1

South Ural State Medical University

D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology

Top-30

Journals

	10 20 30 40 50 60
Multiple Sclerosis and Related Disorders	Multiple Sclerosis and Related Disorders, 58, 14.11% Multiple Sclerosis and Related Disorders 58 publications, 14.11%
Multiple Sclerosis Journal	Multiple Sclerosis Journal, 26, 6.33% Multiple Sclerosis Journal 26 publications, 6.33%
Journal of Neurology	Journal of Neurology, 20, 4.87% Journal of Neurology 20 publications, 4.87%
Neurology: Neuroimmunology and NeuroInflammation	Neurology: Neuroimmunology and NeuroInflammation, 19, 4.62% Neurology: Neuroimmunology and NeuroInflammation 19 publications, 4.62%
Frontiers in Neurology	Frontiers in Neurology, 10, 2.43% Frontiers in Neurology 10 publications, 2.43%
Frontiers in Immunology	Frontiers in Immunology, 8, 1.95% Frontiers in Immunology 8 publications, 1.95%
European Journal of Neurology	European Journal of Neurology, 8, 1.95% European Journal of Neurology 8 publications, 1.95%
Annals of Clinical and Translational Neurology	Annals of Clinical and Translational Neurology, 8, 1.95% Annals of Clinical and Translational Neurology 8 publications, 1.95%
Neurology	Neurology, 7, 1.7% Neurology 7 publications, 1.7%
Journal of Neurology, Neurosurgery and Psychiatry	Journal of Neurology, Neurosurgery and Psychiatry, 6, 1.46% Journal of Neurology, Neurosurgery and Psychiatry 6 publications, 1.46%
Therapeutic Advances in Neurological Disorders	Therapeutic Advances in Neurological Disorders, 5, 1.22% Therapeutic Advances in Neurological Disorders 5 publications, 1.22%
CNS Drugs	CNS Drugs, 5, 1.22% CNS Drugs 5 publications, 1.22%
Neurotherapeutics	Neurotherapeutics, 5, 1.22% Neurotherapeutics 5 publications, 1.22%
Annals of Neurology	Annals of Neurology, 5, 1.22% Annals of Neurology 5 publications, 1.22%
JAMA Neurology	JAMA Neurology, 4, 0.97% JAMA Neurology 4 publications, 0.97%
Multiple Sclerosis Journal - Experimental Translational and Clinical	Multiple Sclerosis Journal - Experimental Translational and Clinical, 4, 0.97% Multiple Sclerosis Journal - Experimental Translational and Clinical 4 publications, 0.97%
Journal of Clinical Medicine	Journal of Clinical Medicine, 4, 0.97% Journal of Clinical Medicine 4 publications, 0.97%
Vaccines	Vaccines, 4, 0.97% Vaccines 4 publications, 0.97%
Current Neurology and Neuroscience Reports	Current Neurology and Neuroscience Reports, 4, 0.97% Current Neurology and Neuroscience Reports 4 publications, 0.97%
Neurological Sciences	Neurological Sciences, 4, 0.97% Neurological Sciences 4 publications, 0.97%
Arquivos de Neuro-Psiquiatria	Arquivos de Neuro-Psiquiatria, 4, 0.97% Arquivos de Neuro-Psiquiatria 4 publications, 0.97%
Expert Review of Neurotherapeutics	Expert Review of Neurotherapeutics, 4, 0.97% Expert Review of Neurotherapeutics 4 publications, 0.97%
Clinical and Experimental Neuroimmunology	Clinical and Experimental Neuroimmunology, 4, 0.97% Clinical and Experimental Neuroimmunology 4 publications, 0.97%
Current Opinion in Neurology	Current Opinion in Neurology, 3, 0.73% Current Opinion in Neurology 3 publications, 0.73%
Revue Neurologique	Revue Neurologique, 3, 0.73% Revue Neurologique 3 publications, 0.73%
Clinical Neurology and Neurosurgery	Clinical Neurology and Neurosurgery, 3, 0.73% Clinical Neurology and Neurosurgery 3 publications, 0.73%
Cochrane Database of Systematic Reviews	Cochrane Database of Systematic Reviews, 3, 0.73% Cochrane Database of Systematic Reviews 3 publications, 0.73%
Expert Opinion on Drug Safety	Expert Opinion on Drug Safety, 3, 0.73% Expert Opinion on Drug Safety 3 publications, 0.73%
medRxiv : the preprint server for health sciences	medRxiv : the preprint server for health sciences, 3, 0.73% medRxiv : the preprint server for health sciences 3 publications, 0.73%
	10 20 30 40 50 60

Publishers

	20 40 60 80 100 120
Elsevier	Elsevier, 102, 24.82% Elsevier 102 publications, 24.82%
Springer Nature	Springer Nature, 68, 16.55% Springer Nature 68 publications, 16.55%
SAGE	SAGE, 39, 9.49% SAGE 39 publications, 9.49%
Wiley	Wiley, 38, 9.25% Wiley 38 publications, 9.25%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 35, 8.52% Ovid Technologies (Wolters Kluwer Health) 35 publications, 8.52%
MDPI	MDPI, 25, 6.08% MDPI 25 publications, 6.08%
Frontiers Media S.A.	Frontiers Media S.A., 21, 5.11% Frontiers Media S.A. 21 publications, 5.11%
Taylor & Francis	Taylor & Francis, 17, 4.14% Taylor & Francis 17 publications, 4.14%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 12, 2.92% Cold Spring Harbor Laboratory 12 publications, 2.92%
BMJ	BMJ, 9, 2.19% BMJ 9 publications, 2.19%
American Medical Association (AMA)	American Medical Association (AMA), 7, 1.7% American Medical Association (AMA) 7 publications, 1.7%
Oxford University Press	Oxford University Press, 5, 1.22% Oxford University Press 5 publications, 1.22%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 3, 0.73% Georg Thieme Verlag KG 3 publications, 0.73%
Media Sphere Publishing House	Media Sphere Publishing House, 3, 0.73% Media Sphere Publishing House 3 publications, 0.73%
The American Association of Immunologists	The American Association of Immunologists, 2, 0.49% The American Association of Immunologists 2 publications, 0.49%
American Society for Clinical Investigation	American Society for Clinical Investigation, 2, 0.49% American Society for Clinical Investigation 2 publications, 0.49%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 2, 0.49% Public Library of Science (PLoS) 2 publications, 0.49%
SciELO	SciELO, 2, 0.49% SciELO 2 publications, 0.49%
Cambridge University Press	Cambridge University Press, 2, 0.49% Cambridge University Press 2 publications, 0.49%
Brieflands	Brieflands, 2, 0.49% Brieflands 2 publications, 0.49%
Remedium, Ltd.	Remedium, Ltd., 2, 0.49% Remedium, Ltd. 2 publications, 0.49%
S. Karger AG	S. Karger AG, 2, 0.49% S. Karger AG 2 publications, 0.49%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 1, 0.24% Bentham Science Publishers Ltd. 1 publication, 0.24%
IOP Publishing	IOP Publishing, 1, 0.24% IOP Publishing 1 publication, 0.24%
Social Science Electronic Publishing	Social Science Electronic Publishing, 1, 0.24% Social Science Electronic Publishing 1 publication, 0.24%
Hindawi Limited	Hindawi Limited, 1, 0.24% Hindawi Limited 1 publication, 0.24%
Mary Ann Liebert	Mary Ann Liebert, 1, 0.24% Mary Ann Liebert 1 publication, 0.24%
Spandidos Publications	Spandidos Publications, 1, 0.24% Spandidos Publications 1 publication, 0.24%
XMLink	XMLink, 1, 0.24% XMLink 1 publication, 0.24%
	20 40 60 80 100 120

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

412

Cite this

GOST |

Cite this

GOST Copy

Luna G. et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies // JAMA Neurology. 2020. Vol. 77. No. 2. p. 184.

GOST all authors (up to 50) Copy

Luna G., Alping P., Burman J., Fink K., Fogdell-Hahn A., Gunnarsson M., Hillert J., Langer-Gould A., Lycke J., Nilsson P., Salzer J., Svenningsson A., Vrethem M., Olsson T., Piehl F., Frisell T. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies // JAMA Neurology. 2020. Vol. 77. No. 2. p. 184.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1001/jamaneurol.2019.3365

UR - https://doi.org/10.1001/jamaneurol.2019.3365

TI - Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

T2 - JAMA Neurology

AU - Luna, Gustavo

AU - Alping, Peter

AU - Burman, Joachim

AU - Fink, Katharina

AU - Fogdell-Hahn, A.

AU - Gunnarsson, M.

AU - Hillert, Jan

AU - Langer-Gould, A.

AU - Lycke, J.

AU - Nilsson, Petra

AU - Salzer, J.

AU - Svenningsson, Anders

AU - Vrethem, Magnus

AU - Olsson, T.

AU - Piehl, Fredrik

AU - Frisell, Thomas

PY - 2020

DA - 2020/02/01

PB - American Medical Association (AMA)

SP - 184

IS - 2

VL - 77

PMID - 31589278

SN - 2168-6149

SN - 2168-6157

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2020_Luna,

author = {Gustavo Luna and Peter Alping and Joachim Burman and Katharina Fink and A. Fogdell-Hahn and M. Gunnarsson and Jan Hillert and A. Langer-Gould and J. Lycke and Petra Nilsson and J. Salzer and Anders Svenningsson and Magnus Vrethem and T. Olsson and Fredrik Piehl and Thomas Frisell},

title = {Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies},

journal = {JAMA Neurology},

year = {2020},

volume = {77},

publisher = {American Medical Association (AMA)},

month = {feb},

url = {https://doi.org/10.1001/jamaneurol.2019.3365},

number = {2},

pages = {184},

doi = {10.1001/jamaneurol.2019.3365}

}

MLA

Cite this

MLA Copy

Luna, Gustavo, et al. “Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.” JAMA Neurology, vol. 77, no. 2, Feb. 2020, p. 184. https://doi.org/10.1001/jamaneurol.2019.3365.

Publisher

American Medical Association (AMA)

Journal

JAMA Neurology

scimago Q1

wos Q1

SJR

6.237

CiteScore

31.0

Impact factor

21.3

ISSN

21686149 (Print)

21686157 (Electronic)